Olomorasib (LY3537982) is a highly selective and potent KRAS G12C inhibitor that irreversibly binds to the KRAS G12C mutant in its inactive GDP-bound state, thereby blocking downstream oncogenic signaling. It exhibits strong antiproliferative activity in KRAS G12C-mutant cancer cell lines, with IC₅₀ values in the sub-nanomolar to low nanomolar range. In vivo studies have demonstrated significant tumor regression in KRAS G12C-mutant xenograft models at well-tolerated doses. Early clinical trials indicate that Olomorasib has favorable oral bioavailability, dose-dependent target engagement, and promising antitumor activity in patients with KRAS G12C-driven cancers, including non-small cell lung cancer (NSCLC).
MedKoo Cat#: 125124
Name: Olomorasib
CAS#: 2649788-46-3
Chemical Formula: C25H19ClF2N4O3S
Exact Mass: 528.0800
Molecular Weight: 528.96
Elemental Analysis: C, 56.77; H, 3.62; Cl, 6.70; F, 7.18; N, 10.59; O, 9.07; S, 6.06
The following data is based on the product molecular weight 528.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
